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Many randomized clinical controlled trials have confirmed the efficacy and safety of calcium dobesilate in treating diabetic 
retinopathy (DR). This systematic review critically evaluated the evidence that links calcium dobesilate to DR.In this 
fixed-effects meta-analysis, a total of 221 pertinent English-language articles published between January 1975 and October 
2013 were identified. Systematic searches of PUBMED, Springer Link and the Cochrane Clinical Trials Database were con-
ducted using the keywords “diabetic retinopathy” and “calcium dobesilate”. The extracted information included the study de-
sign, inclusion and exclusion criteria, setting, sample size, participant mean age, treatment regime, mean change in best cor-
rected visual acuity, laboratory parameters, capillary fragility, intraocular pressure and fundus manifestations based on the 
findings of fluorescent angiography. The summary statistics indicated that calcium dobesilate was significantly associated with 
improving retinal microaneurysms (RR: 0.62, 95%CI: 0.420.90, P=0.01), retinalhemorrhages (RR: 0.39, 95% CI: 0.170.88, 
P=0.02); exudates (RR: 0.31, 95% CI: 0.120.81, P=0.02), reduction of whole blood viscosity (MD: 0.57 CP, 95% CI: 0.75 
to 0.38, P<0.001), plasma viscosity (MD: 0.36 CP, 95% CI: 0.63 to 0.09, P=0.01) and blood cholesterol (MD: 0.48 mg 
mL1, 95% CI: 0.640.33, P<0.00001). Intraocular pressure was also significantly reduced (MD: 5.59 mmHg, 95% CI: 
6.69 to 4.50, P<0.00001). The results indicate that calcium dobesilate effectively treats DR at the systematic and local ocu-
lar levels. 
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Diabetes and its associated complications continue to be a 
significant health problem worldwide. Diabetic retinopathy 
(DR) is the major cause of vision loss and blindness in the 
working populations of developed countries [1]. Overall, the 
global rates for proliferative DR, diabetic macular edema 
and vision-threatening DR are 34.6%, 6.96%, 6.81% and 
10.2%, respectively [2]. The DR rates in the rural and urban 
populations of China are 37% and 42%, respectively [3–5].  
Medical treatment can effectively halt the progression of 
DR, reduce its complication rate and preserve visual func-
tion [6]. Several oral medications, including aspirin [7], 
protein kinase C inhibitor [8], renin-angiotensin blockade [9] 
and candesartan [10], effectively inhibit early DR lesions. 
Calcium dobesilate (2,5-dihydroxybenzenesulfonate) was 
developed for DR and chronic venous insufficiency more 
than 40 years ago. This vasoprotective agent was registered 
by the European Pharmacopoeia in 1997 and the British 
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Pharmacopoeia in 1998 for treating DR and venous insuffi-
ciency. There are seven mechanisms by which calcium 
dobesilate might treat DR: (i) reducing retinal albumin 
leakage and capillary permeability, which protects the 
blood-retinal barrier (BRB) [11]; (ii) inhibiting platelet ag-
gregation and blood viscosity [12]; (iii) up-regulating endo-
thelium-dependent relaxation because of an increase in ni-
tric oxide synthesis [13]; (iv) inhibiting apoptosisof vascular 
endothelial cells in blood vessels [14]; (v) antioxidant and 
antiradical activity [15]; (vi) protecting against reactive ox-
ygen species; or (vii) inhibiting the expression of the in-
flammatory and upstream VEGF regulator, ICAM-1 [16]. 
These pathological factors are likely the most important 
inducers of DR. 
Calcium dobesilate remains the only angioprotective 
drug that reduces the progression of DR, according to sev-
eral randomized clinical trials (RCTs) [17]. Until recently, 
there has been no global data available concerning the ef-
fectiveness of calcium dobesilate in treating DR. Therefore, 
we performed a meta-analysis of the RCTs that compared 
calcium dobesilate and placebo treatments to assess the ef-
fects of this drug and provide the best treatment regimen for 
patients with DR. The source materials for this analysis are 
publicly available. 
1  Methods 
1.1  Data sources and searches 
We searched MEDLINE, Springer Link and the Cochrane 
Library for English-language, human-participant, random-
ized controlled trials (RCTs) published prior to October 31, 
2013. We used the following phrases as keywords: “diabetic 
retinopathy”, “calcium dobesilate” and relevant free terms. 
The Boolean operators “AND”, “OR” and “NOT” were 
used to combine all search sets. References within the re-
trieved studies were examined for additional trials.  
1.2  Study selection 
RCTs concerning the relevant topic were selected based on 
the following criteria: (i) the participants were adults with 
DR; (ii) calcium dobesilate was used as an intervention, and 
a placebo or non-calcium-dobesilate treatment was used as a 
control; and (iii) the primary outcomes included microan-
eurysm, blood viscosity, hemorrhage and exudate im-
provements as well as capillary closure and mean changes 
in the visual acuity, intraocular pressure (IOP) and posterior 
vitreous penetration ratio (PVPR) from baseline to the end 
of the intervention period.  
1.3  Data extraction and quality assessment 
Two reviewers (XY Zhang and SS Wu) independently as-
sessed the eligibility criteria of all studies and extracted the 
relevant information using EpiData Version 3.02 (Odense, 
Denmark). This information included the study author(s), 
publication year, country, sample size, study duration, in-
tervention and control, mean change in visual acuity, blood 
viscosity, PVPR from baseline to the end of the intervention 
period, number of patients whose microaneurysms deterio-
rated, capillary closure, hemorrhage and exudate and meth-
odology information. The data were sorted using Excel 
2007. All discrepancies were resolved by consensus be-
tween the assessors. 
The quality of the included trials was assessed using the 
JADAD scale for RCTs [18], which includes an adequate 
method for randomization, appropriate blinding procedures 
and a detailed report of withdrawals and dropouts.  
1.4  Data analyses  
Data pooling was performed using Review Manager, Ver-
sion 5.1 (Copenhagen: The Nordic Cochrane Centre, the 
Cochrane Collaboration, 2008). Between-group differences 
in the mean changes of visual acuity, blood viscosity and 
PVPR were expressed as weighted mean differences 
(WMDs; i.e., the mean change in the calcium dobesilate 
group minus that in the control group), with 95% confi-
dence intervals (CIs). Risk ratios (RRs) were also calculated, 
with 95% CIs for the microaneurysm, capillary closure, 
hemorrhage and exudate improvements. The heterogeneity 
among studies was evaluated using the χ2 test and I2 statis-
tics, and P<0.1 was considered to be significant for the het-
erogeneity test. A random effects model (Mantel-Haenszel) 
was used to calculate the estimates.  
2  Results 
2.1  Study characteristics  
A total of 221 studies were initially retrieved. After exclud-
ing 57 duplicate reports, four review articles and 34 editori-
als, comment papers or studies that were not eligible, eight 
studies met our inclusion criteria and were reviewed in this 
meta-analysis (see Figure 1 for the study inclusion flow 
diagram). A total of 552 DR patients were examined among 
these eight studies, 306 of whom were treated with calcium 
dobesilate. The mean patient age ranged from 47.28 to 
59.19 years old, and the mean duration of diabetes ranged 
from 3.6 to 15.5 years. The follow-up period ranged from 3 
to 24 months. Additional study characteristics are listed in 
Table 1 [1926].  
2.2  Quality assessment  
Generally, the quality of the included RCTs was moderate 
(Table 2) [1926] . Most RCTs reported the number of par-
ticipants who were lost to follow-up, whereas the randomi-
zation methods used were often unclear. All studies were  
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Figure 1  A patient enrollment flow diagram. 
double blinded.  
2.3  Mean changes in blood viscosity, plasmid viscosity 
and blood cholesterol  
A random effects model was used to analyze the dependent 
variables according to the significant heterogeneity of three 
RCTs with available viscosity data. The pooled mean dif-
ferences of whole blood and plasma viscosities were 
0.57centipoise (CP) (95% CI: 0.75 to 0.38; P<0.001; 
Figure 2) and 0.36 CP (95% CI: 0.63 to 0.09; P=0.01; 
Figure 3).  
Two RCTs reported the data on blood cholesterol reduc-
tions. The pooled mean difference of blood cholesterol re-
duction was 0.48 CP (95% CI: 0.640.33; P<0.00001) 
between calcium dobesilate and placebo groups. However, 
there were no significant differences in blood glyceride lev-
els between the two groups (MD: 2.70 mg mL1; 95% CI: 
16.2310.83; P=0.70; Figure 4).  
2.4  Mean visual acuity change 
We used a random effects model to achieve conservative 
Table 1  Characteristics of the studies included in the meta-analysis 
Study Country Follow up duration Age (years) Diabetes duration (years) Control Intervention (dose, mg d1) 
Larsen et al. [19] Denmark 8 48 15.5 placebo 750 
Vojnikovic et al. [20] Yugoslav 6 55.17 5.05 Placebo 1500 
Leite et al. [21] Portugal 12 53.23 9.88 placebo 2000 
Benarroch et al. [22] Argentina 3 47.28 14.5 placebo 1500 
Vojnikovic et al. [23] Yugoslava 3 57.98 3.6 placebo 1500 
Benarroch et al. [24] Argentina 24 47.34 2.7 placebo 750 
Ribeiro et al. [25] Portugal 24 54.7 8.3 placebo 2000 
Javadzadeh et al. [26] Iran 3 59.19 9.4 placebo 500 
 
 
Figure 2  The effectiveness of calcium dobesilate on blood viscosity. 
 
Figure 3  The effectiveness of calcium dobesilate on plasma viscosity. 
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results; however, significant heterogeneity was not observed 
within two RCTs with available visual acuity data (P=0.19, 
I2=42%). The pooled mean difference between patients tak-
ing calcium dobesilate and those taking a placebo across two 
RCTs was 0.05 D (95% CI: 0.000.11, P=0.07; Figure 5).  
2.5  Microaneurysm, hemorrhaging, capillary closure 
and exudates improvements 
2.5.1  Microaneurysm 
Three RCTs reported the number of patients whose pro-
gression deteriorated with regard to microaneurysm, and 
significant heterogeneity differences did not exist between 
these RCTs (P=0.91, I2=0%). We used a random effects 
model to pool the data and observed that the likelihood of 
microaneurysm improvement significantly increased in the 
calcium dobesilate group (RR: 0.62, 95% CI: 0.420.90, 
P=0.01; Figure 6).  
2.5.2  Retinal hemorrhages 
Two RCTs provided the improvement count data of retinal  
hemorrhages. No significant differences in heterogeneity 
were found between the two RCTs (P=0.20, I2=40%). A 
random effects model found that the risk of decreased pro-
gress toward retinal hemorrhages changed significantly (RR: 
0.39, 95% CI: 0.170.88, P=0.02; Figure 7). 
2.5.3  Capillary closure 
Two RCTs reported the numbers of patients who demonstrat-
ed worse capillary closure progression. Significant heteroge-
neity was not found between these RCTs (P=0.11, I2=60%). 
A random effects model revealed that the risk of decreased 
progress toward capillary closure did not significantly change 
(RR: 0.87, 95% CI: 0.089.54, P=0.91; Figure 8). 
2.5.4  Exudates 
Two RCTs provided specific information concerning the 
improvement of retinal exudation. Significant heterogeneity 
was not observed between these RCTs (P=0.18, I2=45%). A 
random effects model revealed that the risk of decreased 
progress toward exudates changed significantly (RR: 0.31, 
95% CI: 0.120.81, P=0.02; Figure 9). 
Table 2  The quality of enrolled RCTsa) 
Study Study type Randomization Blinding Lost to follow up Jadadscore 
Larsen et al. [19] RCT 1 2 1 4 
Vojnikovic et al. [20] RCT 1 2 1 4 
Leite et al. [21] RCT 2 2 1 5 
Benarroch et al. [22] RCT 1 2 1 4 
Vojnikovic et al. [23] RCT 1 2 1 4 
Benarroch et al. [24] RCT 1 2 0 3 
Ribeiro et al. [25] RCT 1 2 1 4 
Javadzadeh et al. [26] RCT 2 2 0 4 




Figure 4  The effectiveness of calcium dobesilate on blood cholesterol. 
 
Figure 5  A comparison of the effectiveness of calcium dobesilate on the mean change in visual acuity. 
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Figure 6  A comparison of the effectiveness of calcium dobesilate on microaneurysm improvement. 
 
Figure 7  A comparison of the effectiveness of calcium dobesilate on fundus hemorrhage improvement. 
 
Figure 8  A comparison of the effectiveness of calcium dobesilate on fundus capillary closure improvement. 
 
Figure 9  A comparison of the effectiveness of calcium dobesilate on fundus exudate improvement. 
2.6  Reduction of the intraocular pressure  
Two studies reported the reduction of IOP. Significant het-
erogeneity was found between these two RCTs. The pooled 
mean differences of IOP reduction between the two groups 
was 5.59 mmHg (95% CI: 6.69 to 4.50, P<0.00001; 
Figure 10). 
2.7  Mean change in the function of the BRB (i.e., the 
PVPR) 
Two RCTs reported data concerning a functional evaluation 
of the BRB. The pooled mean difference in PVPR was 
2.77 (95% CI: 8.222.68, P=0.32; Figure 11). 
3  Discussion 
The results of the present systematic review suggested that 
an oral intake of 7502000 mg d1 of calcium dobesilate 
effectively treats DR compared with placebo. Microaneu-
rysm, exudates and retinal hemorrhages can be significantly 
improved; blood parameters, such as whole-blood viscosity, 
plasma viscosity and cholesterol, were greatly reduced to  
106 Zhang XY, et al.   Sci China Life Sci   January (2015) Vol.58 No.1 
 
Figure 10  A comparison of the effectiveness of calcium dobesilate on intraocular pressure. 
 
Figure 11  A comparison of the effectiveness of calcium dobesilate on the mean change in function of the blood retinal barrier breakdown (i.e., the PVPR). 
normal ranges after a 3-month treatment.   
This systematic review examined eight randomized, con-
trolled studies, with a total of 552 patients. All studies ful-
filled the inclusion criteria. The large sample size and ran-
domization allocation indicate a substantial increase in sta-
tistical precision. The ratio of males to females was ap-
proximately equal. The studies were conducted in the US 
and Europe and involved different races and patient charac-
teristics. 
Calcium dobesilate has antioxidant, anti-radical and an-
gioprotective properties. Furthermore, this medicine acts 
against the capillary permeability induced by reactive oxy-
gen species, enhanced nitric oxide synthase activity in en-
dothelial cells, anti-apoptotic effects in vessels and other 
tissues and inhibitory effects of inflammatory cytokines. 
Blood viscosity reductions have been well studied in vivo 
and in vitro. To our knowledge, this systematic review is the 
first to evaluate the effectiveness of calcium dobesilate 
among DR patients on a global basis. 
Vascular leakage is a key method of evaluating the effec-
tiveness of calcium dobesilate. The breakdown of the BRB 
is an early sign of vascular damage. Several methods have 
been applied to evaluate the function of BRB among RCTs 
and animal studies, including vitreous fluorophotometry 
[27], PVPR [25], vascular fragility [28], skin capillary re-
sistance [19,23] and the penetration ratio [21]. Albumin 
leakage [29] indicates the successful treatment of capillary 
fragility in DR patients. Although the BRB was significant-
ly protected in these studies, data could not be extracted or 
pooled together from these studies; thus, a meta-analysis 
could not be conducted. 
Two of the eight studies showed that elevated IOP can be 
significantly reduced [20,24]. However, more detailed in-
formation such as if eye drops were used to control IOP was 
not provided; furthermore, a large, multi-center study is 
warranted to confirm the conclusion. 
Previous population-based studies [30,31] have shown 
that hyperlipidemia is a risk factor for developing DR and 
for the progression of the disease. Hyperlipidemia contrib-
utes to DR and ME via endothelial dysfunction and the 
breakdown of the BRB, which leads to the exudation of 
serum lipids and lipoproteins. These effects are significantly 
correlated with DR severity [3234]. The RCTs examined 
in this paper confirmed that calcium dobesilate reduces the 
serum level of blood hyperglycemia; thus, this paper pro-
vides justification to prohibit the progression of DR and 
protect the BRB [23]. 
The limitations of the current paper include the relatively 
small sample sizes of the analyzed studies. Furthermore, 
these data did not originate from multicenter, collaborative 
studies. A lack of detailed methods regarding the randomi-
zation procedures might increase the chances for bias and 
error. We also recommend that the methodological quality 
of clinical trials seeking to evaluate drugs be improved in 
the future using random allocation concealment to prevent 
selection bias [35] and long-term follow-up assessments 
that use internationally accepted, uniform and objective 
indicators of efficacy [36,37]. Furthermore, the negative 
results, placebo control groups, number of patients lost   
to follow-up and lost patient records must be reported in 
detail [38].  
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